Actithera is pioneering chemistries in radioligand therapy that extend tumor residence time, creating differentiated candidates like its lead fibroblast activation protein-targeted compound.

-Series A financing led by Sanofi Ventures with participation from Atlas Venture, Access Biotechnology, Vertex Ventures HC, Digitalis Ventures, Alexandria Venture Investments, and others CAMBRIDGE, ...

EMERYVILLE, Calif., Oct. 27, 2022 /PRNewswire/ -- Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced ...

Matchpoint Therapeutics has publicly launched with $70 million in series A financing and an earlier $30 million in seed money to develop covalent drugs for immune diseases. Its founders include ...

In a recent study posted to the bioRxiv* preprint server, researchers performed an extensive library docking for new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) ...

BUFFALO, N.Y. — One class of drugs that has shown promise in treating diseases ranging from lung cancer to COVID-19 are targeted covalent inhibitors (TCIs). These small molecule drugs form covalent ...

Misbehaving proteins are behind many diseases. One way drugmakers incapacitate these bad actors is to deploy molecules that bind to them. But finding solid footholds on the proteins to block their ...

Molly Gibson, PhD, has focused her attention on building companies at the intersection of AI and life sciences for the past decade, having co-founded both Generate: Biomedicines and Lila Sciences.

The Chemical Nomenclature STEM Certificate is a self-guided program that provides guidance on rules related to naming in chemistry, including: binary compounds, Types I & II ionic compounds, ...

Senescent cells walk a tightrope, risking cell death with high levels of iron and other damaging agents, but compensating for this by overproducing a protective protein, GPX4, which staves off death.